Abstract

The Program Leaders for the Markey Cancer Center (MCC) provide cohesive leadership for promoting the research activities within and among the program areas. They assure continued interchange, program planning and evaluation, and educational exchange within their program. The Program Leaders identify areas of need within their research program and work with leadership of the cancer center to establish priorities and pursue recruitment in their respective areas. They are involved in identifying the shared resource needs of their program members and encourage collaborations between programs by communicating with leaders of other programs on possible areas of interactions and collaborations. They inform the appropriate Associate Director and the MCC Director on program activities and serve on the MCC's Scientific Advisory Panel and the Program and Shared Resource Leaders Committee. The four research programs of the MCC) are: Program 1: Cancer Cell Biology and Signaling Program 2: Cancer Prevention and Control Program 3: Drug Discovery, Delivery and Translational Therapeutics Program 4: Redox Injury and Repair

Public Health Relevance

The four Markey Cancer Center research programs provide an exchange of scientific knowledge with their program members and with members of the other research programs by collaborating on innovative research studies.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA177558-01
Application #
8740614
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-07-08
Project End
2018-06-30
Budget Start
2013-07-08
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$120,920
Indirect Cost
$40,306

  Institution

Name
University of Kentucky
Department
Type
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506

  Publications

Al-Darraji, Ahmed; Haydar, Dalia; Chelvarajan, Lakshman et al. (2018) Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease. PLoS One 13:e0200474
Jarrett, Stuart G; Carter, Katharine M; Bautista, Robert-Marlo et al. (2018) Sirtuin 1-mediated deacetylation of XPA DNA repair protein enhances its interaction with ATR protein and promotes cAMP-induced DNA repair of UV damage. J Biol Chem 293:19025-19037
Zaytseva, Yekaterina Y; Rychahou, Piotr G; Le, Anh-Thu et al. (2018) Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget 9:24787-24800
Choi, Yohan; Rosewell, Katherine L; Brännström, Mats et al. (2018) FOS, a Critical Downstream Mediator of PGR and EGF Signaling Necessary for Ovulatory Prostaglandins in the Human Ovary. J Clin Endocrinol Metab 103:4241-4252
Jiang, Kai; Liu, Yajuan; Zhang, Jie et al. (2018) An intracellular activation of Smoothened that is independent of Hedgehog stimulation in Drosophila. J Cell Sci 131:
Dhar, Sanjit K; Bakthavatchalu, Vasudevan; Dhar, Bithika et al. (2018) DNA polymerase gamma (Pol?) deficiency triggers a selective mTORC2 prosurvival autophagy response via mitochondria-mediated ROS signaling. Oncogene 37:6225-6242
Engle, Jeff A; Traynor, Anne M; Campbell, Toby C et al. (2018) Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. J Oncol Pharm Pract 24:348-353
Kim, Ji Tae; Napier, Dana L; Weiss, Heidi L et al. (2018) Neurotensin Receptor 3/Sortilin Contributes to Tumorigenesis of Neuroendocrine Tumors Through Augmentation of Cell Adhesion and Migration. Neoplasia 20:175-181
Gedaly, Roberto; De Stefano, Felice; Turcios, Lilia et al. (2018) mTOR Inhibitor Everolimus in Regulatory T cell Expansion for Clinical Application in Transplantation. Transplantation :
Pi, Fengmei; Binzel, Daniel W; Lee, Tae Jin et al. (2018) Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13:82-89

Showing the most recent 10 out of 359 publications